Compare AIFA & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIFA | SCLX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 27.9M |
| IPO Year | 2017 | 2020 |
| Metric | AIFA | SCLX |
|---|---|---|
| Price | $4.00 | $2.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 387.2K | 38.6K |
| Earning Date | 11-18-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,655,039.00 | ★ $30,253,000.00 |
| Revenue This Year | N/A | $118.16 |
| Revenue Next Year | N/A | $186.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.50 | N/A |
| 52 Week Low | $1.52 | $2.52 |
| 52 Week High | $8.93 | $27.00 |
| Indicator | AIFA | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 45.06 | 17.44 |
| Support Level | $2.80 | N/A |
| Resistance Level | $8.93 | $7.77 |
| Average True Range (ATR) | 0.78 | 0.35 |
| MACD | -0.28 | -0.06 |
| Stochastic Oscillator | 4.96 | 0.93 |
All In FutureTech Alliance Inc operates an AI-focused digital infrastructure platform. Its activities include opportunities in AI infrastructure, silicon photonics-enabled computing, fiber-optic network transmission, digital infrastructure services, and technology-related initiatives. The company is also developing the AIFA platform, which is intended to combine AI computing capacity, fiber-optic network infrastructure, AI education, and AI-related applications.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.